We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 29.83 | 30.18 | 30.22 | 121 | 14:14:45 |
From May 2019 to May 2024
By Cecilia Butini
Roche Holding AG said Monday that its eye treatment Faricimab met its primary endpoint in two phase 3 studies.
The Swiss pharmaceutical major said the studies evaluated the drug--an investigational bispecific antibody--in people with neovascular age-related macular degeneration. They showed that people receiving Faricimab injections at intervals of up to 16 weeks achieved noninferior visual acuity outcomes compared with use of a different drug.
The company said Faricimab was generally well tolerated and didn't present new or unexpected safety signals.
The two studies were Tenaya and Lucerne, Roche said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
January 25, 2021 01:29 ET (06:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
